Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RLYB116

Peptide · Inhibitor of Complement C5 (C5) · developed by Rallybio

Phase 1 Most advanced trial (none active)
RLYB Developer
1 Registered trials

What is RLYB116?

RLYB116 is a small protein built from an Affibody Z-domain that binds complement C5 with high affinity and inhibits terminal complement activation, plus an albumin-binding domain that extends its plasma half-life. It is being studied in hematologic diseases and autoimmune diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Targets
Complement C5 (C5)
Mechanism
Inhibitor of Complement C5 (C5)
Pathways
terminal complement activation
Therapy area
Hematology, Immunology
Developer
Rallybio (RLYB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06797375 Phase 1 Hematologic Diseases Completed RLYB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autoimmune DiseasesHematologic Diseases

Other drugs acting on C5

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RLYB page.

Follow RLYB, the company behind RLYB116

See RLYB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RLYB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.